Blue Jet Healthcare's stock experienced a dramatic sell-off, hitting a 52-week low of ₹357.75 on Monday, February 16, 2026, after reporting disappointing third-quarter fiscal year 2026 earnings. The stock was trading down 9% at ₹360.40 by mid-morning on Monday, contrasting with a marginal rise in the BSE Sensex. This represents a significant reversal, with the stock now trading near its IPO issue price of ₹346 and has already fallen approximately 47.87% over the past year. The stock's current P/E ratio stands around 19.6x, which is favorable when compared to the Indian Pharmaceuticals industry average of 27.1x and peer averages of 29.1x, though this valuation differential appears insufficient to counter immediate concerns.
The company faced substantial revenue headwinds during the quarter, as reported by CNBC TV18 and Business Standard. Revenue from operations plummeted 39.6% year-on-year to ₹1,924 crore, primarily attributed to a sharp contraction in sales volumes within the pharmaceutical intermediate (PI) segment, which faced inventory challenges and customer de-stocking, alongside weak performance in artificial sweeteners. The gross profit declined 42.8% year-on-year to ₹99.6 crore, with gross profit margins contracting by 290 basis points year-on-year to 51.7%. This margin pressure was exacerbated by destocking, lower sweetener prices, and higher raw material costs. EBITDA contracted by 62.2% to ₹46.9 crore, with EBITDA margins falling to 24.4%, a significant reduction from 39% in Q3 FY25. Net profit dropped 59.4% year-on-year to ₹40.2 crore.
The stark financial results have led to a deeply divided opinion among market analysts. ICICI Securities maintained a 'BUY' rating while acknowledging gross profit margin volatility and bempedoic acid revenue concerns, but significantly revised their earnings per share estimates downwards by 12-22% for FY26-28 and slashed their price target to ₹500 from ₹750. In contrast, Emkay Global Financial Services reiterated a 'Reduce' rating, cutting earnings estimates by approximately 25% and reducing their price target to ₹400 from ₹600. MarketsMojo downgraded their rating from 'Hold' to 'Sell' in early January 2026, citing expensive valuation and flat financial trends. Despite the current turbulence, Blue Jet Healthcare possesses several inherent strengths, including a diversified global footprint exporting to over 50 countries with approximately 87% of revenue generated internationally.
The primary concern for investors revolves around the company's ambitious capital expenditure plan of ₹1,300 crore over the next three to four years for capacity expansion, product development, backward integration, and establishing an R&D center. While intended to fuel future growth, this substantial investment introduces significant execution risks, including timely project commissioning, potential cost escalations, and achieving planned capacity utilization. The company's balance sheet, while strong with negligible debt as of March 2025, could face pressure if the new capacities do not ramp up as expected. Historical stock performance indicates a pattern of sharp declines following earnings misses, suggesting that execution missteps could lead to prolonged stock weakness.
